Bethany Sensenig net worth and biography

Bethany Sensenig Biography and Net Worth

Ms. Sensenig was most recently Chief Financial Officer and Interim Chief Executive Officer of 9 Meters Biopharma, a clinical-stage biotechnology company. Prior to that, Ms. Sensenig was Chief Financial Officer and Head of U.S. Operations of Minovia Therapeutics, Ltd., a clinical-stage biotechnology company, where she played a critical leadership role in building the company's business and financing strategy. She spent 13 years at Biogen Inc., a multinational biotechnology company, where she held several positions of increasing responsibility, the latest of which was Vice President of Finance and Commercial Operations. Ms. Sensenig has played key roles in numerous transactions and acquisition-related deals totaling over $2 billion across Biogen and Minovia and had direct P&L accountability at Biogen for upwards of $1 billion in annual revenue across 30 countries spanning the U.S., Asia-Pacific, Latin America and Europe. Earlier in her career, Ms. Sensenig held financial management and analyst roles at Merck & Co. Inc. and Nexus Technologies, Inc.

What is Bethany Sensenig's net worth?: The estimated net worth of Bethany Sensenig is at least $1.85 million as of April 21st, 2023. Ms. Sensenig owns 41,077 shares of Supernus Pharmaceuticals stock worth more than $1,852,573 as of December 4th. This net worth approximation does not reflect any other assets that Ms. Sensenig may own. Learn More about Bethany Sensenig's net worth.
How do I contact Bethany Sensenig?: The corporate mailing address for Ms. Sensenig and other Supernus Pharmaceuticals executives is 1550 E GUDE DR, ROCKVILLE MD, 20850. Supernus Pharmaceuticals can also be reached via phone at (301) 838-2500 and via email at [email protected]. Learn More on Bethany Sensenig's contact information.
Has Bethany Sensenig been buying or selling shares of Supernus Pharmaceuticals?: Bethany Sensenig has not been actively trading shares of Supernus Pharmaceuticals during the last quarter. Most recently, Bethany Sensenig sold 5,369 shares of the business's stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $42.25, for a transaction totalling $226,840.25. Learn More on Bethany Sensenig's trading history.
Who are Supernus Pharmaceuticals' active insiders?: Supernus Pharmaceuticals' insider roster includes Padmanabh Bhatt (Senior Vice President, Chief Scientific Officer, Intellectual Property), Timothy Dec (CFO), Georges Gemayel (Director), Frederick Hudson (Director), Jack Khattar (President and Chief Executive Officer, Director), Frank Mottola (SVP, GMP Operations, IT and Regulatory Affairs), Jonathan Rubin (Senior Vice President, Chief Medical Officer, Research & Development), and Bethany Sensenig (Director). Learn More on Supernus Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Supernus Pharmaceuticals?: In the last twelve months, insiders at the specialty pharmaceutical company sold shares 16 times. They sold a total of 373,845 shares worth more than $16,830,854.81. The most recent insider tranaction occured on October, 9th when CEO Jack A Khattar sold 59,900 shares worth more than $3,029,143.00. Insiders at Supernus Pharmaceuticals own 8.8% of the company. Learn More about insider trades at Supernus Pharmaceuticals.
Information on this page was last updated on 10/9/2025.

Bethany Sensenig Insider Trading History at Supernus Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/14/2025	Sell	5,369	$42.25	$226,840.25

Bethany Sensenig Buying and Selling Activity at Supernus Pharmaceuticals

Supernus Pharmaceuticals Company Overview

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Today's Range

Now: $45.10

$44.28

$45.10

50 Day Range

MA: $48.40

$44.12

$57.00

2 Week Range

Now: $45.10

$29.16

$57.65

Volume

493,657 shs

Average Volume

807,434 shs

Market Capitalization

$2.59 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71